Who
Paul Varki
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Avalo Therapeutics; SVP, GC & Chief Compliance Off, Egalet.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $3.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Oct 2016
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K1,081 at $13.10 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K1,081 at $13.10 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,300 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,300 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $839K62,500 at $13.43 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $101K12,563 at $8.04 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $707K37,375 at $18.91 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,563 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K5,196 at $19.78 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $485K22,839 at $21.22 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $210K9,253 at $22.70 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,484400 at $23.71 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $839K62,500 at $13.43 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $101K12,563 at $8.04 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $707K37,375 at $18.91 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K5,196 at $19.78 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $485K22,839 at $21.22 | filing |
| 6 May 2026filed 7 May 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $210K9,253 at $22.70 | filing |
News
Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Paul Varki; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.